Full Signal is a subscription-based health tracking app for individuals on GLP-1 therapies, focused on medication scheduling and symptom logging.
Product velocity
Active
Daily rank 🇺🇸
—
Health & Fitness
Sentiment
—
—
Nemesis
Shotsy GLP-1 Tracker
The App DNA
What makes this app unique?
Users hire the app to maintain medication consistency and monitor physical well-being without the mental load of calorie counting or complex data entry.
For Individuals undergoing GLP-1 therapies who require a low-friction, non-cluttered method to monitor their weekly medication and physical well-being.
Key features
Weekly shot logging with pre-set medication, dose, and timing configurations
Visualization of user-reported feelings and trends over time
Low-friction interface for logging daily feelings without forms or scrolling
How much does it cost?
Subscription-only model gates all core tracking and insight features to ensure recurring revenue from the start.
Velocity
Active developmentUX improvementsperformanceShow more...
Full Signal is currently in an active development phase, shipping three updates over the past 25 days, which averages to roughly 0.8 releases per week. The development team is focused on functional improvements, specifically regarding GLP-1 therapy tracking, dosage accuracy, and schedule flexibility. The release history shows a consistent effort to refine the core user experience rather than relying on live-ops events. The current cadence is stable and suggests a responsive development cycle aimed at addressing user feedback and edge cases in the scheduling logic.
Who built it?
TRISTAN ROBERT NOHRER
5 apps tracked · Health & Fitness
Couch X Crawler
That Counts Today
LexInvaders
JunkCamUser Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for Full Signal
How's the Health & Fitness market?
Full Signal enters a crowded health-tracking market where established rivals hold significant review-count leads. The subscription-only barrier requires high perceived value to convert users against free, ad-supported alternatives.
Read the market outlookThe rivals identified
By Shotsy
Shotsy is the direct market leader for GLP-1 users, offering a specialized tracking experience that mirrors Full Signal’s core value proposition of medication consistency and symptom monitoring.
- Provides advanced medication level estimation algorithms that Full Signal currently lacks for predictive insights
- Boasts a massive user base and high review volume, creating a strong social proof barrier
- Offers deep multi-medication scheduling capabilities that cater to complex patient treatment regimens
Low-Carb Diet & Meal PlannerContender
Medisafe Carezone: PillMemoContender
GLP 1 Tracker - Within ReachContender
Cuspart: Blood SugarContenderUnlock the head-to-head verdict: where this rival wins, and where it loses.
Access the full report for freeThe Analyst's Read
Key takeaways for Full Signal
Where is it heading?
The GLP-1 tracking market is consolidating around apps that offer both ease-of-use and clinical utility. Full Signal's current posture is advantaged by its simplicity, but it must add predictive features to prevent users from migrating to more data-rich competitors.
- The app launched recently with a focused feature set, establishing a baseline for future expansion into predictive health analytics.
The SWOT
- Low-friction interface removes tracking burden
- Pattern-based insights provide value beyond raw logging
- Wearable health data integration
- B2B partnerships with clinics
Next best moves
Ship predictive medication-level modeling because it is the primary utility gap vs Shotsy → increase long-term retention
The counter-intuitive read
The subscription-only model is a strategic advantage, not a weakness…
Read the full takeFeature gaps
Predictive medication level estimation (available in Shotsy) +1
Since the last report: The app removed interoperability features like Apple Health and data export, shifting its roadmap toward predictive medication modeling to compete with market leader Shotsy.
Bottom line
Full Signal succeeds by simplifying the GLP-1 tracking experience, but the lack of predictive clinical features leaves it vulnerable to established rivals, so the PM should prioritize adding medication-level modeling to defend against churn.
Unlock 2 critical frictions, 2 market threats and the analyst’s take.
Access the full report for freeReport last updated